PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
暂无分享,去创建一个
R. Bernards | C. Sotiriou | S. Loi | M. Piccart | C. Denkert | J. Baselga | S. Loibl | M. Untch | V. Nekljudova | G. von Minckwitz | C. Schem | I. Majewski | P. Conte | E. Bria | V. Guarneri | E. Holmes